Cellebrite DI Statistics
Total Valuation
Cellebrite DI has a market cap or net worth of $4.52 billion. The enterprise value is $3.98 billion.
Important Dates
The next estimated earnings date is Wednesday, November 5, 2025, before market open.
| Earnings Date | Nov 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Cellebrite DI has 244.47 million shares outstanding. The number of shares has increased by 17.65% in one year.
| Current Share Class | 244.47M |
| Shares Outstanding | 244.47M |
| Shares Change (YoY) | +17.65% |
| Shares Change (QoQ) | -0.13% |
| Owned by Insiders (%) | 2.65% |
| Owned by Institutions (%) | 39.63% |
| Float | 112.43M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 36.43 |
| PS Ratio | 9.74 |
| Forward PS | 8.70 |
| PB Ratio | 11.07 |
| P/TBV Ratio | 12.23 |
| P/FCF Ratio | 30.11 |
| P/OCF Ratio | 28.06 |
| PEG Ratio | 2.38 |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 53.46, with an EV/FCF ratio of 26.54.
| EV / Earnings | n/a |
| EV / Sales | 9.12 |
| EV / EBITDA | 53.46 |
| EV / EBIT | 62.30 |
| EV / FCF | 26.54 |
Financial Position
The company has a current ratio of 1.96, with a Debt / Equity ratio of 0.05.
| Current Ratio | 1.96 |
| Quick Ratio | 1.82 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | 0.28 |
| Debt / FCF | 0.15 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -81.98% and return on invested capital (ROIC) is 19.87%.
| Return on Equity (ROE) | -81.98% |
| Return on Assets (ROA) | 5.95% |
| Return on Invested Capital (ROIC) | 19.87% |
| Return on Capital Employed (ROCE) | 13.40% |
| Revenue Per Employee | $374,235 |
| Profits Per Employee | -$129,347 |
| Employee Count | 1,167 |
| Asset Turnover | 0.65 |
| Inventory Turnover | 7.45 |
Taxes
In the past 12 months, Cellebrite DI has paid $6.43 million in taxes.
| Income Tax | 6.43M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +6.82% in the last 52 weeks. The beta is 1.29, so Cellebrite DI's price volatility has been higher than the market average.
| Beta (5Y) | 1.29 |
| 52-Week Price Change | +6.82% |
| 50-Day Moving Average | 16.37 |
| 200-Day Moving Average | 18.32 |
| Relative Strength Index (RSI) | 61.13 |
| Average Volume (20 Days) | 1,503,932 |
Short Selling Information
The latest short interest is 8.02 million, so 3.28% of the outstanding shares have been sold short.
| Short Interest | 8.02M |
| Short Previous Month | 5.77M |
| Short % of Shares Out | 3.28% |
| Short % of Float | 7.13% |
| Short Ratio (days to cover) | 3.58 |
Income Statement
In the last 12 months, Cellebrite DI had revenue of $436.73 million and -$150.95 million in losses. Loss per share was -$0.66.
| Revenue | 436.73M |
| Gross Profit | 368.50M |
| Operating Income | 63.96M |
| Pretax Income | -144.52M |
| Net Income | -150.95M |
| EBITDA | 74.53M |
| EBIT | 63.96M |
| Loss Per Share | -$0.66 |
Full Income StatementBalance Sheet
The company has $472.18 million in cash and $22.33 million in debt, giving a net cash position of $535.51 million or $2.19 per share.
| Cash & Cash Equivalents | 472.18M |
| Total Debt | 22.33M |
| Net Cash | 535.51M |
| Net Cash Per Share | $2.19 |
| Equity (Book Value) | 408.41M |
| Book Value Per Share | 1.67 |
| Working Capital | 296.14M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $161.08 million and capital expenditures -$10.95 million, giving a free cash flow of $150.13 million.
| Operating Cash Flow | 161.08M |
| Capital Expenditures | -10.95M |
| Free Cash Flow | 150.13M |
| FCF Per Share | $0.61 |
Full Cash Flow StatementMargins
Gross margin is 84.38%, with operating and profit margins of 14.64% and -34.56%.
| Gross Margin | 84.38% |
| Operating Margin | 14.64% |
| Pretax Margin | -33.09% |
| Profit Margin | -34.56% |
| EBITDA Margin | 17.07% |
| EBIT Margin | 14.64% |
| FCF Margin | 34.38% |
Dividends & Yields
Cellebrite DI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -17.65% |
| Shareholder Yield | -17.65% |
| Earnings Yield | -3.34% |
| FCF Yield | 3.32% |
Dividend DetailsAnalyst Forecast
The average price target for Cellebrite DI is $22.60, which is 22.23% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $22.60 |
| Price Target Difference | 22.23% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 15.62% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Cellebrite DI has an Altman Z-Score of 7.45 and a Piotroski F-Score of 5.
| Altman Z-Score | 7.45 |
| Piotroski F-Score | 5 |
